HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection
The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls...
Saved in:
| Published in | Retrovirology Vol. 9; no. 1; p. 76 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
20.09.2012
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection.
Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies.
These data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. |
|---|---|
| AbstractList | BACKGROUNDThe potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection. RESULTSNeutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies. CONCLUSIONSThese data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. Background: The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection. Results: Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies. Conclusions: These data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. Doc number: 76 Abstract Background: The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection. Results: Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies. Conclusions: These data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. Abstract Background The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection. Results Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies. Conclusions These data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. Background The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection. Results Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies. Conclusions These data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. Keywords: HIV-1 superinfection, Subtype C, Neutralizing antibodies, HIV-1 transmission, HIV-1 dual infection The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection. Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies. These data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection. Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies. These data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates. |
| ArticleNumber | 76 |
| Audience | Academic |
| Author | Hraber, Peter T Mulenga, Joseph Kilembe, William Allen, Susan A Basu, Debby Irene, Carmela Pinter, Abraham Yu, Tianwei Kraft, Colleen S Hunter, Eric Chomba, Elwyn Murphy, Megan K Campbell, Patricia J Derdeyn, Cynthia A |
| AuthorAffiliation | 5 Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA 3 Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA 10 Department of Pathology, Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, Georgia, 30329, USA 2 Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA 6 Los Alamos National Laboratory, Los Alamos, New Mexico, USA 9 Projet San Francisco, Kigali, Rwanda 1 Immunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, GA, USA 8 Zambia Emory HIV Research Project, Lusaka, Zambia 7 Public Health Research Institute Center, New Jersey Medical School, Newark, UMDNJ, New Jersey, USA 4 Emory University, Atlanta, Georgia, USA |
| AuthorAffiliation_xml | – name: 2 Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA – name: 10 Department of Pathology, Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, Georgia, 30329, USA – name: 9 Projet San Francisco, Kigali, Rwanda – name: 3 Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA – name: 5 Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA – name: 6 Los Alamos National Laboratory, Los Alamos, New Mexico, USA – name: 4 Emory University, Atlanta, Georgia, USA – name: 7 Public Health Research Institute Center, New Jersey Medical School, Newark, UMDNJ, New Jersey, USA – name: 1 Immunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, GA, USA – name: 8 Zambia Emory HIV Research Project, Lusaka, Zambia |
| Author_xml | – sequence: 1 givenname: Debby surname: Basu fullname: Basu, Debby organization: Immunology and Molecular Pathogenesis Graduate Program, Emory University, Atlanta, GA, USA – sequence: 2 givenname: Colleen S surname: Kraft fullname: Kraft, Colleen S – sequence: 3 givenname: Megan K surname: Murphy fullname: Murphy, Megan K – sequence: 4 givenname: Patricia J surname: Campbell fullname: Campbell, Patricia J – sequence: 5 givenname: Tianwei surname: Yu fullname: Yu, Tianwei – sequence: 6 givenname: Peter T surname: Hraber fullname: Hraber, Peter T – sequence: 7 givenname: Carmela surname: Irene fullname: Irene, Carmela – sequence: 8 givenname: Abraham surname: Pinter fullname: Pinter, Abraham – sequence: 9 givenname: Elwyn surname: Chomba fullname: Chomba, Elwyn – sequence: 10 givenname: Joseph surname: Mulenga fullname: Mulenga, Joseph – sequence: 11 givenname: William surname: Kilembe fullname: Kilembe, William – sequence: 12 givenname: Susan A surname: Allen fullname: Allen, Susan A – sequence: 13 givenname: Cynthia A surname: Derdeyn fullname: Derdeyn, Cynthia A – sequence: 14 givenname: Eric surname: Hunter fullname: Hunter, Eric |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22995123$$D View this record in MEDLINE/PubMed https://www.osti.gov/servlets/purl/1626610$$D View this record in Osti.gov |
| BookMark | eNqNk82L1DAYxousuB969ShFL1665qtpcxGGQd2BBS_qNeSr3QxtMibpynj1Hzd1dscZXUFaaHjzy_O-fR5yXpw470xRPIfgEsKWvoENQRWhDFSsauij4mxfODlYnxbnMa4BwLAF7ZPiFCHGaojwWfHjavWlgmWcZNpuTLnMq40J1nVGJaNL67S9tXoSQyxHP7lUDv5bKabkB9_7KZbOTCmIwX63ri-FS1Z6vS2DiRvvoonlJlgfyuSzUubu2xw0sd49LR53uYF5dve9KD6_f_dpeVVdf_ywWi6uK0kpS1XdQoYaRjugBSO4g52ikrasQ5rVhNWtaBqMiGAYmQaolmJNoWKCSEEY6iS-KFY7Xe3FmufJRhG23AvLfxV86LkIyarBcAq71mhoNKkxgQpJqbGRmEnUdFoKmrXe7rQ2kxyNVmb-veFI9HjH2Rve-1uOSdMAzLLAy52Aj8nyqGwy6kZ557InHFJEKQQZWuwgaf0_uhzvKD_yOXU-p84Zb-ZJX99NGvzXycTERxuVGQbhTE6QQ4zaGgL2PyiE2WdA2Iy--gNd-ym4HN9MobYFgKDfVC-yqTlwn6dUsyhfZGMRy2-TqcsHqPxoM9psielsrj90QAUfYzDd3hEI-Hwt_vbgxWFae_z-HuCfsXULbQ |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0160341 crossref_primary_10_3389_fmicb_2020_00021 crossref_primary_10_1371_journal_pone_0166746 crossref_primary_10_1007_s11684_017_0594_8 crossref_primary_10_1097_QAI_0b013e3182874d41 crossref_primary_10_1128_JVI_02260_13 crossref_primary_10_1093_infdis_jiv136 crossref_primary_10_1128_JVI_02308_13 crossref_primary_10_1371_journal_ppat_1003593 crossref_primary_10_1016_j_vaccine_2017_11_075 crossref_primary_10_1097_COH_0000000000000553 crossref_primary_10_1128_JVI_03090_15 crossref_primary_10_1371_journal_pone_0093235 crossref_primary_10_1128_JVI_00187_14 crossref_primary_10_1371_journal_pone_0072295 crossref_primary_10_1126_science_1256526 crossref_primary_10_1016_j_virol_2014_06_016 crossref_primary_10_1186_s12977_017_0343_8 crossref_primary_10_1089_aid_2015_0324 crossref_primary_10_1016_j_ebiom_2017_04_005 crossref_primary_10_1016_S1473_3099_13_70066_5 crossref_primary_10_1128_JVI_00475_17 crossref_primary_10_1371_journal_pone_0173705 crossref_primary_10_1097_QAI_0000000000001420 crossref_primary_10_1016_j_idc_2014_08_004 crossref_primary_10_1016_j_virol_2019_06_009 |
| Cites_doi | 10.1128/JVI.00201-06 10.1371/journal.ppat.1000433 10.1128/JVI.01730-06 10.1371/journal.ppat.0030177 10.1128/JVI.00198-11 10.1128/JVI.02732-09 10.1097/QAI.0b013e31815d2f3f 10.1126/science.1187659 10.1186/1758-2652-14-18 10.1016/j.jaci.2003.08.037 10.1016/S0140-6736(08)60953-8 10.1016/j.virol.2010.04.010 10.1038/nm.2528 10.1128/JVI.02216-10 10.1038/nm833 10.1186/1742-4690-9-22 10.1038/nm.1974 10.1016/j.immuni.2010.09.011 10.1038/nature01200 10.1128/JVI.00239-07 10.1038/ni.2264 10.1126/science.1093137 10.1186/1471-2458-7-349 10.1073/pnas.0504658102 10.1371/journal.ppat.1000598 10.1371/journal.ppat.1000594 10.1093/bioinformatics/btg412 10.1128/JVI.02660-07 10.1016/S0264-410X(98)00182-0 10.1038/nature01470 10.1038/nature06106 10.1128/JVI.73.5.4009-4018.1999 10.1371/journal.ppat.1002611 10.1128/JVI.02108-09 10.1371/journal.ppat.1000274 10.1097/COH.0b013e32832ea7e8 10.1128/JVI.01730-08 10.1007/978-1-4614-1743-9 10.1038/nm.1949 10.1128/JVI.02006-10 10.1038/72318 10.1128/JVI.76.1.397-405.2002 10.1128/JVI.73.12.10489-10502.1999 10.1073/pnas.0630530100 10.1056/NEJMoa1113425 10.1016/j.virol.2006.08.009 10.1097/00002030-200303280-00012 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 BioMed Central Ltd. 2012 Basu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2012 Basu et al.; licensee BioMed Central Ltd. 2012 Basu et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2012 BioMed Central Ltd. – notice: 2012 Basu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2012 Basu et al.; licensee BioMed Central Ltd. 2012 Basu et al.; licensee BioMed Central Ltd. |
| CorporateAuthor | Los Alamos National Laboratory (LANL), Los Alamos, NM (United States) |
| CorporateAuthor_xml | – name: Los Alamos National Laboratory (LANL), Los Alamos, NM (United States) |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 OIOZB OTOTI 5PM DOA |
| DOI | 10.1186/1742-4690-9-76 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic OSTI.GOV - Hybrid OSTI.GOV PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Virology and AIDS Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database AIDS and Cancer Research Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1742-4690 |
| EndPage | 76 |
| ExternalDocumentID | oai_doaj_org_article_61f8ed1ed45341c2bbd3eb39b27fdba6 1626610 oai_biomedcentral_com_1742_4690_9_76 2792252551 A534294297 10_1186_1742_4690_9_76 22995123 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States Atlanta Georgia Georgia |
| GeographicLocations_xml | – name: United States – name: Atlanta Georgia – name: Georgia |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R56 AI091514-01A1 – fundername: NIAID NIH HHS grantid: R01 AI-58706 – fundername: NIAID NIH HHS grantid: P30 AI050409 – fundername: NCATS NIH HHS grantid: UL1 TR000454 – fundername: NIAID NIH HHS grantid: U01 AI-78410 – fundername: NIAID NIH HHS grantid: T32 AI-007470 – fundername: NCRR NIH HHS grantid: P51RR165 – fundername: NIAID NIH HHS grantid: R37 AI051231 – fundername: NCATS NIH HHS grantid: KL2 TR000455 – fundername: NIH HHS grantid: P51OD11132 |
| GroupedDBID | --- -A0 0R~ 123 29P 2VQ 2WC 3V. 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB AAYXX CITATION 7U9 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 7X8 ABVAZ AFGXO AFNRJ AFPKN AAPBV ABPTK N95 OIOZB OTOTI 5PM ACUHS |
| ID | FETCH-LOGICAL-b669t-58192796f0da943f1fc6b689f2d954958a77324a932e70c863d61c9a4ba492fb3 |
| IEDL.DBID | RBZ |
| ISSN | 1742-4690 |
| IngestDate | Tue Dec 17 15:18:19 EST 2024 Tue Sep 17 21:11:13 EDT 2024 Mon Jul 10 02:33:11 EDT 2023 Wed May 22 07:15:17 EDT 2024 Fri Oct 25 04:46:45 EDT 2024 Fri Oct 25 07:38:58 EDT 2024 Thu Oct 10 19:06:58 EDT 2024 Tue Nov 19 21:30:52 EST 2024 Tue Nov 12 23:35:12 EST 2024 Thu Nov 21 23:20:05 EST 2024 Tue Oct 15 23:40:48 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b669t-58192796f0da943f1fc6b689f2d954958a77324a932e70c863d61c9a4ba492fb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 AC52-06NA25396 USDOE Office of Science (SC), Biological and Environmental Research (BER). Biological Systems Science Division |
| OpenAccessLink | http://dx.doi.org/10.1186/1742-4690-9-76 |
| PMID | 22995123 |
| PQID | 1112880042 |
| PQPubID | 54665 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_61f8ed1ed45341c2bbd3eb39b27fdba6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3477039 osti_scitechconnect_1626610 biomedcentral_primary_oai_biomedcentral_com_1742_4690_9_76 proquest_miscellaneous_1328510976 proquest_miscellaneous_1114950496 proquest_journals_1112880042 gale_infotracmisc_A534294297 gale_infotracacademiconefile_A534294297 crossref_primary_10_1186_1742_4690_9_76 pubmed_primary_22995123 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-09-20 |
| PublicationDateYYYYMMDD | 2012-09-20 |
| PublicationDate_xml | – month: 09 year: 2012 text: 2012-09-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: United States |
| PublicationTitle | Retrovirology |
| PublicationTitleAlternate | Retrovirology |
| PublicationYear | 2012 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – sequence: 0 name: BMC – name: BioMed Central Ltd – name: BioMed Central |
| References | 10196297 - J Virol. 1999 May;73(5):4009-18 22513323 - Nat Immunol. 2012 May;13(5):423-7 12459786 - Nature. 2002 Nov 28;420(6914):434-9 10559367 - J Virol. 1999 Dec;73(12):10489-502 18072974 - BMC Public Health. 2007;7:349 9795384 - Vaccine. 1998 Nov;16(19):1803-11 17409164 - J Virol. 2007 Jun;81(12):6187-96 21389135 - J Virol. 2011 May;85(10):4828-40 12646921 - Nature. 2003 Mar 20;422(6929):307-12 18586173 - Lancet. 2008 Jun 28;371(9631):2183-91 12644702 - Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 16339909 - Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18514-9 19763269 - PLoS Pathog. 2009 Sep;5(9):e1000594 19525965 - Nat Med. 2009 Aug;15(8):951-4 14610465 - J Allergy Clin Immunol. 2003 Nov;112(5):829-35; quiz 836 19436712 - PLoS Pathog. 2009 May;5(5):e1000433 17805298 - Nature. 2007 Sep 6;449(7158):101-4 20616233 - Science. 2010 Aug 13;329(5993):856-61 12646797 - AIDS. 2003 Mar 28;17(5):733-40 20048698 - Curr Opin HIV AIDS. 2009 Sep;4(5):358-63 21029964 - Immunity. 2010 Oct 29;33(4):542-54 21477317 - J Int AIDS Soc. 2011;14:18 18256145 - J Virol. 2008 Apr;82(8):3952-70 11739704 - J Virol. 2002 Jan;76(1):397-405 19763271 - PLoS Pathog. 2009 Sep;5(9):e1000598 20980495 - J Virol. 2011 Jan;85(2):905-15 20631143 - J Virol. 2010 Sep;84(18):9415-26 19525964 - Nat Med. 2009 Aug;15(8):866-70 22475592 - N Engl J Med. 2012 Apr 5;366(14):1275-86 20494390 - Virology. 2010 Aug 15;404(1):59-70 22479183 - PLoS Pathog. 2012;8(3):e1002611 19165325 - PLoS Pathog. 2009 Jan;5(1):e1000274 9376093 - AIDS. 1997 Sep;11 Suppl 1:S103-10 16962152 - Virology. 2006 Nov 10;355(1):1-5 16971434 - J Virol. 2006 Dec;80(23):11776-90 12579198 - Nat Med. 2003 Mar;9(3):343-6 18020705 - PLoS Pathog. 2007 Nov;3(11):e177 21411521 - J Virol. 2011 Jun;85(11):5252-61 16699001 - J Virol. 2006 Jun;80(11):5211-8 21988997 - Nat Med. 2011 Oct;17(10):1195-7 10655111 - Nat Med. 2000 Feb;6(2):207-10 19939925 - J Virol. 2010 Feb;84(3):1439-52 18030162 - J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):116-25 15044802 - Science. 2004 Mar 26;303(5666):2019-22 14734327 - Bioinformatics. 2004 Jan 22;20(2):289-90 18842728 - J Virol. 2008 Dec;82(24):12094-103 22433432 - Retrovirology. 2012;9:22 X Wu (3349_CR49) 2010; 329 PL Moore (3349_CR32) 2009; 5 A Pinter (3349_CR30) 1998; 16 SA Trask (3349_CR42) 2002; 76 RL Powell (3349_CR14) 2010; 84 E Paradis (3349_CR47) 2004; 20 RM Lynch (3349_CR23) 2011; 85 ES Gray (3349_CR26) 2007; 81 DM Smith (3349_CR13) 2006; 355 SD Frost (3349_CR35) 2005; 102 M Altfeld (3349_CR12) 2002; 420 AJ McMichael (3349_CR9) 2012; 13 DD Richman (3349_CR36) 2003; 100 CA Derdeyn (3349_CR21) 2004; 303 S Allen (3349_CR18) 2007; 7 DI Boeras (3349_CR40) 2011; 14 TJ Hope (3349_CR38) 2011; 17 JR Mascola (3349_CR5) 2000; 6 MS Seaman (3349_CR28) 2010; 84 ES Gray (3349_CR33) 2011; 85 TM Allen (3349_CR1) 2003; 112 PL Moore (3349_CR31) 2009; 4 AJ Hessell (3349_CR37) 2007; 449 AJ Hessell (3349_CR3) 2009; 5 JF Salazar-Gonzalez (3349_CR45) 2008; 82 V Cortez (3349_CR15) 2012; 8 L Bragg (3349_CR16) 2010 MC Kempf (3349_CR41) 2008; 47 L Stamatatos (3349_CR34) 2009; 15 RE Haaland (3349_CR44) 2009; 5 A Piantadosi (3349_CR11) 2007; 3 R Shankarappa (3349_CR20) 1999; 73 RS Veazey (3349_CR7) 2003; 9 B Li (3349_CR22) 2006; 80 AJ Hessell (3349_CR2) 2009; 15 X Wei (3349_CR25) 2003; 422 M Li (3349_CR27) 2006; 80 BF Haynes (3349_CR8) 2012; 366 CA Blish (3349_CR10) 2008; 82 JB Lynch (3349_CR48) 2011; 85 E Paradis (3349_CR46) 2012 CS Kraft (3349_CR19) 2012; 9 R Rong (3349_CR29) 2009; 5 RM Lynch (3349_CR24) 2010; 404 S Allen (3349_CR43) 2003; 17 MJ McElrath (3349_CR6) 2010; 33 JR Mascola (3349_CR4) 1999; 73 SL McKenna (3349_CR39) 1997; 11 KL Dunkle (3349_CR17) 2008; 371 |
| References_xml | – volume: 80 start-page: 5211 year: 2006 ident: 3349_CR22 publication-title: J Virol doi: 10.1128/JVI.00201-06 contributor: fullname: B Li – volume: 5 start-page: e1000433 year: 2009 ident: 3349_CR3 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000433 contributor: fullname: AJ Hessell – volume: 80 start-page: 11776 year: 2006 ident: 3349_CR27 publication-title: J Virol doi: 10.1128/JVI.01730-06 contributor: fullname: M Li – volume: 3 start-page: e177 year: 2007 ident: 3349_CR11 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.0030177 contributor: fullname: A Piantadosi – volume: 85 start-page: 4828 year: 2011 ident: 3349_CR33 publication-title: J Virol doi: 10.1128/JVI.00198-11 contributor: fullname: ES Gray – volume: 84 start-page: 9415 year: 2010 ident: 3349_CR14 publication-title: J Virol doi: 10.1128/JVI.02732-09 contributor: fullname: RL Powell – volume: 47 start-page: 116 year: 2008 ident: 3349_CR41 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e31815d2f3f contributor: fullname: MC Kempf – volume: 329 start-page: 856 year: 2010 ident: 3349_CR49 publication-title: Science doi: 10.1126/science.1187659 contributor: fullname: X Wu – volume: 14 start-page: 18 year: 2011 ident: 3349_CR40 publication-title: J Int AIDS Soc doi: 10.1186/1758-2652-14-18 contributor: fullname: DI Boeras – volume: 112 start-page: 829 year: 2003 ident: 3349_CR1 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2003.08.037 contributor: fullname: TM Allen – volume: 371 start-page: 2183 year: 2008 ident: 3349_CR17 publication-title: Lancet doi: 10.1016/S0140-6736(08)60953-8 contributor: fullname: KL Dunkle – volume: 404 start-page: 59 year: 2010 ident: 3349_CR24 publication-title: Virology doi: 10.1016/j.virol.2010.04.010 contributor: fullname: RM Lynch – volume: 17 start-page: 1195 year: 2011 ident: 3349_CR38 publication-title: Nat Med doi: 10.1038/nm.2528 contributor: fullname: TJ Hope – volume: 85 start-page: 5252 year: 2011 ident: 3349_CR48 publication-title: J Virol doi: 10.1128/JVI.02216-10 contributor: fullname: JB Lynch – volume: 9 start-page: 343 year: 2003 ident: 3349_CR7 publication-title: Nat Med doi: 10.1038/nm833 contributor: fullname: RS Veazey – volume: 9 start-page: 22 year: 2012 ident: 3349_CR19 publication-title: Retrovirology doi: 10.1186/1742-4690-9-22 contributor: fullname: CS Kraft – volume: 15 start-page: 951 year: 2009 ident: 3349_CR2 publication-title: Nat Med doi: 10.1038/nm.1974 contributor: fullname: AJ Hessell – volume: 33 start-page: 542 year: 2010 ident: 3349_CR6 publication-title: Immunity doi: 10.1016/j.immuni.2010.09.011 contributor: fullname: MJ McElrath – volume: 11 start-page: S103 issue: Suppl 1 year: 1997 ident: 3349_CR39 publication-title: AIDS contributor: fullname: SL McKenna – volume: 420 start-page: 434 year: 2002 ident: 3349_CR12 publication-title: Nature doi: 10.1038/nature01200 contributor: fullname: M Altfeld – volume: 81 start-page: 6187 year: 2007 ident: 3349_CR26 publication-title: J Virol doi: 10.1128/JVI.00239-07 contributor: fullname: ES Gray – volume: 13 start-page: 423 year: 2012 ident: 3349_CR9 publication-title: Nat Immunol doi: 10.1038/ni.2264 contributor: fullname: AJ McMichael – volume: 303 start-page: 2019 year: 2004 ident: 3349_CR21 publication-title: Science doi: 10.1126/science.1093137 contributor: fullname: CA Derdeyn – volume: 7 start-page: 349 year: 2007 ident: 3349_CR18 publication-title: BMC Publ Health doi: 10.1186/1471-2458-7-349 contributor: fullname: S Allen – volume: 102 start-page: 18514 year: 2005 ident: 3349_CR35 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0504658102 contributor: fullname: SD Frost – volume: 5 start-page: e1000598 year: 2009 ident: 3349_CR32 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000598 contributor: fullname: PL Moore – volume: 5 start-page: e1000594 year: 2009 ident: 3349_CR29 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000594 contributor: fullname: R Rong – volume: 20 start-page: 289 year: 2004 ident: 3349_CR47 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btg412 contributor: fullname: E Paradis – volume: 82 start-page: 3952 year: 2008 ident: 3349_CR45 publication-title: J Virol doi: 10.1128/JVI.02660-07 contributor: fullname: JF Salazar-Gonzalez – volume-title: Abstract Conference on Retroviruses and Opportunistic Infections year: 2010 ident: 3349_CR16 contributor: fullname: L Bragg – volume: 16 start-page: 1803 year: 1998 ident: 3349_CR30 publication-title: Vaccine doi: 10.1016/S0264-410X(98)00182-0 contributor: fullname: A Pinter – volume: 422 start-page: 307 year: 2003 ident: 3349_CR25 publication-title: Nature doi: 10.1038/nature01470 contributor: fullname: X Wei – volume: 449 start-page: 101 year: 2007 ident: 3349_CR37 publication-title: Nature doi: 10.1038/nature06106 contributor: fullname: AJ Hessell – volume: 73 start-page: 4009 year: 1999 ident: 3349_CR4 publication-title: J Virol doi: 10.1128/JVI.73.5.4009-4018.1999 contributor: fullname: JR Mascola – volume: 8 start-page: e1002611 year: 2012 ident: 3349_CR15 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1002611 contributor: fullname: V Cortez – volume: 84 start-page: 1439 year: 2010 ident: 3349_CR28 publication-title: J Virol doi: 10.1128/JVI.02108-09 contributor: fullname: MS Seaman – volume: 5 start-page: e1000274 year: 2009 ident: 3349_CR44 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1000274 contributor: fullname: RE Haaland – volume: 4 start-page: 358 year: 2009 ident: 3349_CR31 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0b013e32832ea7e8 contributor: fullname: PL Moore – volume: 82 start-page: 12094 year: 2008 ident: 3349_CR10 publication-title: J Virol doi: 10.1128/JVI.01730-08 contributor: fullname: CA Blish – start-page: 1 volume-title: Analysis of Phylogenetics and Evolution with R, Second Edition year: 2012 ident: 3349_CR46 doi: 10.1007/978-1-4614-1743-9 contributor: fullname: E Paradis – volume: 15 start-page: 866 year: 2009 ident: 3349_CR34 publication-title: Nat Med doi: 10.1038/nm.1949 contributor: fullname: L Stamatatos – volume: 85 start-page: 905 year: 2011 ident: 3349_CR23 publication-title: J Virol doi: 10.1128/JVI.02006-10 contributor: fullname: RM Lynch – volume: 6 start-page: 207 year: 2000 ident: 3349_CR5 publication-title: Nat Med doi: 10.1038/72318 contributor: fullname: JR Mascola – volume: 76 start-page: 397 year: 2002 ident: 3349_CR42 publication-title: J Virol doi: 10.1128/JVI.76.1.397-405.2002 contributor: fullname: SA Trask – volume: 73 start-page: 10489 year: 1999 ident: 3349_CR20 publication-title: J Virol doi: 10.1128/JVI.73.12.10489-10502.1999 contributor: fullname: R Shankarappa – volume: 100 start-page: 4144 year: 2003 ident: 3349_CR36 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0630530100 contributor: fullname: DD Richman – volume: 366 start-page: 1275 year: 2012 ident: 3349_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa1113425 contributor: fullname: BF Haynes – volume: 355 start-page: 1 year: 2006 ident: 3349_CR13 publication-title: Virology doi: 10.1016/j.virol.2006.08.009 contributor: fullname: DM Smith – volume: 17 start-page: 733 year: 2003 ident: 3349_CR43 publication-title: AIDS doi: 10.1097/00002030-200303280-00012 contributor: fullname: S Allen |
| SSID | ssj0031808 |
| Score | 2.174042 |
| Snippet | The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody... Background The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early... Doc number: 76 Abstract Background: The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We... BACKGROUNDThe potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early... Background: The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early... BACKGROUND: The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early... Abstract Background The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early... |
| SourceID | doaj pubmedcentral osti biomedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 76 |
| SubjectTerms | Acquired immune deficiency syndrome AIDS Antibodies Antibodies, Neutralizing - blood BASIC BIOLOGICAL SCIENCES Case-Control Studies Cell Line Comparative analysis Development and progression Disease transmission Genetic aspects Genomes Genomics Health aspects HIV HIV (Viruses) HIV Antibodies - blood HIV Envelope Protein gp120 - genetics HIV Envelope Protein gp120 - immunology HIV infection HIV Infections - blood HIV Infections - immunology HIV Infections - virology HIV-1 - genetics HIV-1 - immunology HIV-1 dual infection HIV-1 superinfection HIV-1 transmission Human immunodeficiency virus Human immunodeficiency virus 1 Humans Immune response Immunity, Humoral Immunoglobulin A Immunoglobulin A - blood Immunoglobulin G Immunoglobulin G - blood Infection Infections Medical research Molecular Sequence Data Neutralizing antibodies Peptide Fragments - immunology Phylogeography Physiological aspects Plasma Risk factors Sequence Analysis, DNA Studies Subtype C Superinfection - virology Vaccines Viral antibodies Virology |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pi9QwFA4yIHgRf9vdVSIInsK2aZs23tbFZRT05MreQtOmOLC2y7RFdq_7j_u9tlMmKnrxNjQv6TTvy8v32pf3GHsNzqFreGwiysNCJC7Jhc2zUigb6kLqJLTjh_ZPn9X6PPl4kV7slfqimLApPfA0cccqqnNXRa5KUhjcUlpbxXAAtZVZXdliSrYdyp0zNdlgAHWsRQe6LQU5gHO6xihXx8s1oQVlGvHOuV9629OYxX-x1asWi-5PRPTXeMq9DersAbs_M0t-Mj3RQ3bHNY_Y3anW5PVjdrv-8FVEvBssvXXlp_hFSY7HWCxX8c1yMKvj36l-BL9sf_BiGMvbtkPHGzeML0VusNdxqGNj2-qab6cQW9fxq-2m3fK-xUiQ291m7yYAwBN2fvb-y-lazBUYhFVK9yKldGmZVnVYFTqJ66gulVW5rmVFnwfTvMgyMLICJNBlYZmruFJRqYvEFomWtY2fslXTNu4547GOa7AdQEbBJYcCVepCa2HeZF6r0AbsracIczVl2zCU_9pvwVI0pEVDWjTaZCpgb3ZaW_qN3k2ufpN8R0r1Rh8vAHNmxpz5F-ZwO4KEIRuAf1QW81EGPCll0zIn6AacS50F7MiTxNotveZDApUB26GUvSXFNpW9iRTRphCdd1gzs2XpyGOTsLmwtQF7tTTTuBQt1zgggmSgHPh-6i8ymPeUwg8g82yC7zIpEhwFRDAOWOYB25s1v6XZfBtzk8dJhj1EH_yPaT5k90BPJUXnyPCIrfrt4F6AAvb25bjafwLW71v5 priority: 102 providerName: Directory of Open Access Journals – databaseName: PubMed Central dbid: RPM link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbalZC4IN4sLchISJzcTZzED25lRbUgFXGgqDcrdhyItJus9iFUrv3jnXEeagriwG21Hj_ieX2TjMeEvAXMoUuI2FisopylPlXMKumYsJHOuU4jGz60n38Ri4v082V2eUCy_ixMSNp3tjqpl6uTuvoZcivXKzfr88RmX8_nSSpBUPXskByC--1D9Nb8goxGqqvOGCsxA8TNGcaATDOJFxZxMMDg5ZI7J9yXI8cU6vcPVnrSgLr9DYLezaS85ZrOHpIHHaakp-3aH5EDXz8m99pbJq-ekOvFp-8sptu9xfetdA6_sLxxyMLyBa2GI1lbusKbI-iy-UXzfbjYttlvae334XXIb_ByFBhR2aa4ops2udZv6XpTNRu6a2AkoOunuTUJsP4puTj7-G2-YN3dC8wKoXcsw0JpUosyKnKdJmVcOmGF0iUv8MNgpnIpAYvlAP-8jJwSSSFip_PU5qnmpU2ekUnd1P4FoYlOSsA5ICwCgnGbaJH5yFowbFyVIrJT8n7ECLNu62wYrHw9bgElNMhQgww12kgxJe96rg39QlyjxB-UH5Cpo9HDH83mh-mky4i4VL6IfZFm4N4dt7ZIPCzZclkWNsfpUCQMaj-syOXdIQZ4UqyjZU6hG0g413JKjkeUoLVu1HyEQmUA52CxXodZTW5nYoGAKYLOvayZzqZsMVbjYG3Byk7Jm6EZx8U8udqDRCANMAeiPvEPGtj3DBMPgOZ5K77DpvTKMSVyJNijXRu3gJKGquSdUr78755H5D6gUY7JODw6JpPdZu9fAeLb2ddBw28AIWpZFQ priority: 500 providerName: National Library of Medicine – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA96h-CL-G3dlAiCT2Ft2qaJL7KNjavgEHGyt9CkqV6Y7bUfyHz1H_ecNq2ryt4uNycfzfmd5Jfk5ISQl8A5VAkrNhbJMGeJSyQzMrNMmFDlXCWhGQ7a35-K9Vny7jw99xturXernMbEYaAuaot75PtgkxywBhh7s_3O8NUoPF31T2jcJDs8iqVckZ3D49MPH6exGAAbSh-qMZJiH-g3Z7ggZIphlJHFHfeLxdQ0RPCfx-lVDQb3PxL6ty_llcnp5C6541klPRhhcI_ccNV9cmt8Z_LyAfm1fvuZRbTtDe640iP4hQGOBz8sV9DNfCmrpd_w7Qh6Uf-geT88bVv3La1cP2yI_IR5joIqNqYuLmkzute6lm6bTd3QroaSQG6q5koloPyH5Ozk-NPRmvnXF5gRQnUsxVBpmRJlWOQqicuotMIIqUpe4NFgKvMsAzaWAwF0WWiliAsRWZUnJk8UL038iKyqunJPCI1VXALTAbgIWI6bWInUhcbA0MZlKUITkNcLRejtGGlDY-zrZQpAQqMWNWpRK52JgLyatDbnG1Y2UvwjeYhKXZQ-_FE3X7Q3VC2iUroickWSwgRvuTFF7KDJhmdlYXKsDiGh0f6hRTb31xjgSzGSlj6AbIBxrrKA7C0kwW7tInkXQaWB6WC4Xot-TbbTkUDKFELmCWvajyqt_mMDAXkxJ2O56ClXOUAEyoByYN0nrpGBfk_R9QBkHo_wnTuFAz8BEhgHJFsAe9Fry5Rq83WISx4nGcwf6un1Td8lt4F0cvS54eEeWXVN754BsevMc2-9vwFbd1Fk priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEA-6IvgiflvvlAiCT9E2TZNGEDkPj1U4n1y5t9C0qS6s7dkPdH31H3cm7dbr3eGLb0szSbqZmcxvmskMIc8Ac-gSPDYWpWHGhBMps6nKmbShzrgWofUH7ccf5XIlPpwkJ3_jn8YFbC917bCe1KrZvPj5ffsGFP61V_hUvgRQzRm6eUwzJa-SaxysIoZ3HYvpRAEe-Op0E-2YwPFi_3M33zczg-Xz-k-796IGNbwMmp6PsDxjso5ukZsj1qQHg3DcJldcdYdcH6pPbu-S38v3n1lE297id1h6CL8w7bGPznIFXU9XtVr6DStK0E39g2a9L3hb9y2tXO8_k_wC60eBQWtbF1vaDEG3rqWnzbpuaFfDSEC3m-bMJCAS98jq6N2nwyUbazIwK6XuWIIJ1JSWZVhkWsRlVObSylSXvMADwyTNlAKMlgEsdCrMUxkXMsp1JmwmNC9tfJ8sqrpyDwmNdVwC_gEhkuCk21jLxIXWwobH01KGNiCvZowwp0P-DYMZsectoJwGuWiQi0YbJQPyfMe1qZ_3d1J5gfItMnU2un9QN1_MqL5GRmXqisgVIgGzn3Nri9jBK1uuysJmOB2KhEE5hTfKs_FyA_xTzK9lDqAbSD7XKiD7M0rQ5nzWvIdCZQD_YBLfHKOd8s5EEoFUCJ13smZ2qoI-HIddGHbfgDydmnFcjJ-rHEgE0gBzwBuU_6CBdU8wIAFoHgziOy0KB9QC0DAOiJoJ9mzV5i3V-qvPVh4LBVZFP_ofbu6RGwBUOcbp8HCfLLqmd48BDHb2idfyP8WyX_o priority: 102 providerName: Scholars Portal |
| Title | HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22995123 https://www.proquest.com/docview/1112880042 https://search.proquest.com/docview/1114950496 https://search.proquest.com/docview/1328510976 http://dx.doi.org/10.1186/1742-4690-9-76 https://www.osti.gov/servlets/purl/1626610 https://pubmed.ncbi.nlm.nih.gov/PMC3477039 https://doaj.org/article/61f8ed1ed45341c2bbd3eb39b27fdba6 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYJyReEN-EjcpISDxZJE7iD97aaVOptAkNhiperDhxtEojmdpUaLzyj3PnpGHpEC-8tFV8tlPf-e539vlMyFvAHLoEj41FKsxY4hLFrJI5EzbUGddJaP1G--mZmF0k80W6-LPesbODHynxHiAzZ-jEMc2k2CP74DDE6GadT79tdS4Ipr97rqft0jPerb9zrv1qYI581v5eN49qmGR_A5678ZO3DNLJI_KwQ5J00rL-Mbnnqifkfnu35M1T8mv28SuL6HpjcZWVHsEvTGrsY69cQZf9Qaw1_Y73RdCr-gfNNv4623qzppXb-EWQn2DbKAz_0tbFDV21IbVuTa9Xy3pFmxpaArptN7c6AYY_Ixcnx1-OZqy7cYFZIXTDUkyPJrUowyLTSVxGZS6sULrkBW4HpiqTEhBYBqDPyTBXIi5ElOsssVmieWnj52RU1ZV7SWis4xLQDYiIABfcxlqkLrQW1BlXpQhtQD4MGGGu2-waBvNdD0tg6hnkokEuGm2kCMi7Ldf6et6bUeIO5RSZOmjdPwARM93kNCIqlSsiVyQpGPWcW1vEDl7ZclkWNsPuUCQMznl4ozzrji7AP8XsWWYC1UCuuZYBORxQwlzNB8UHKFQG0A2m6M0xlilvTCQQJoVQeStrptMka_TQOOhY0K0BedMXY7sYHVc5kAikAeaAryf-QQPjnmK4AdC8aMW3HxQOmASAXxwQORDswagNS6rlpc9FHicSbIZ-9T_cPCAPAIZyjMLh4SEZNauNew1Qr7FjsicXckz2J5P55zl8T4_PPp2P_cIJfJ4mauz1wNiv0v0GH3ZZXQ |
| link.rule.ids | 108,230,314,727,780,784,864,885,2102,2221,12056,21388,24318,24937,27924,27925,31719,31720,33744,33745,43310,43805,53791,53793,75811,75812 |
| linkProvider | BioMedCentral |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgK0QviDehBYyExMlq4iSOzQW1VasttCuEWtSbZScOrNQmyyYRKlf-ODN50QDqbbUeP-L5xv5sj8eEvAHOoXJYsbFA-oZFLpLMyiRlwvrKcBX5tj1oP1mI-Vn04Tw-7zfcqt6tchgT24E6K1PcI98Bm-SANcDY-9V3hq9G4elq_4TGbbKBkdPjGdnYO1h8-jyMxQBYX_ahGgMpdoB-c4YLQqYYRhmZ3HG_mExNbQT_cZyelWBw_yOhf_tSXpucDu-Tez2rpLsdDB6QW654SO5070xePSK_5kdfWECrxuKOK92HXxjguPXDchldjpeyKnqJb0fQi_IHNU37tG3ZVLRwTbsh8hPmOQqqWNoyu6Lrzr3WVXS1XpZrWpdQEsgN1VyrBJT_mJwdHpzuz1n_-gKzQqiaxRgqLVEi9zOjojAP8lRYIVXOMzwajKVJEmBjBgigS_xUijATQapMZE2keG7DJ2RWlIV7RmiowhyYDsBFwHLchkrEzrcWhjYuc-Fbj7ybKEKvukgbGmNfT1MAEhq1qFGLWulEeOTtoLUxX7uykeIfyT1U6qT09o9y_VX3hqpFkEuXBS6LYpjgU25tFjposuVJnlmD1SEkNNo_tCg1_TUG-FKMpKV3IRtgnKvEI9sTSbDbdJK8haDSwHQwXG-Kfk1prQOBlMmHzAPWdD-qVPqPDXjk9ZiM5aKnXOEAESgDyoF1n7hBBvo9RtcDkHnawXfsFA78BEhg6JFkAuxJr01TiuW3Ni55GCUwf6jnNzf9Fbk7Pz051sdHi49bZBMIKEf_G-5vk1m9btwLIHm1fdlb8m9EF1RM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdGEYiXic_RbYCRkHgyS5zEjnnbBlXHx4QQQxMvVpzYUFGSKk2Fxiv_OHdOGjUb4oW3qD7bqe_n8--c85mQZ8A5lAOPjYVpkLHYxikzqcyZMIHKuIoD4z-0vz8V07P4zXlyvkWm67MwtW3Qla79nvKLzSPoc2-34SH_frAoXDvdU3EAlJozdPKYYlJcI9eBAfsp-vHoy9omA3D93XS9bJe-8Wr9S-fe54Plymf17233qIJJ-Ddiejm-cmPBmtwm2x3TpIctNO6QLVveJTfauycv7pHf05PPLKTLlcFdWHoMT5j02Mdm2YLO-oNaS_oD75Og8-onzVb-uttqtaSlXflNkl-w9lFQz8xUxQWt25Bbu6SLelbVtKmgJZBbd7PRCQDiPjmbvP50PGXdjQzMCKEalmD6NKmEC4pMxZELXS6MSJXjBX4uTNJMSmBoGZBCK4M8FVEhwlxlsclixZ2JHpBRWZX2IaGRihywH4CQABfdREokNjAGzB1PnQjMmLwcKEIv2uwbGvNhD0sAFxq1qFGLWmkpxuT5Wmt9Pe_tpOKK5BEqddC6_6Gqv-pu8moRutQWoS3iBBb9nBtTRBZe2XDpCpNhdwgJjTYBAZp1Rxvgn2J2LX0I1QD3XMkx2R9IwlzOB8V7CCoN7AdT-OYY65Q3OhRIowKovMaa7izNEj04DjYYbO-YPO2LsV2MnistIAJlQDngC4p_yMC4JxiOADI7LXz7QeHAWYAYRmMiB8AejNqwpJx987nKo1jCmqJ2_0ebT8jND68m-t3J6ds9cgsYK8eAHR7sk1FTr-wjYIWNeewn_B8nomIb |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIV-1+subtype+C+superinfected+individuals+mount+low+autologous+neutralizing+antibody+responses+prior+to+intrasubtype+superinfection&rft.jtitle=Retrovirology&rft.au=Basu%2C+Debby&rft.au=Kraft%2C+Colleen&rft.au=Murphy%2C+Megan&rft.au=Campbell%2C+Patricia&rft.date=2012-09-20&rft.pub=BioMed+Central+Ltd&rft.issn=1742-4690&rft.eissn=1742-4690&rft.volume=9&rft.issue=1&rft.spage=76&rft.epage=76&rft_id=info:doi/10.1186%2F1742-4690-9-76&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_1742_4690_9_76 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1742-4690&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1742-4690&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1742-4690&client=summon |